HIGH RISK MYELODYSPLASTIC SYNDROME

This early-stage study tests a new drug, CBX-250, in people with certain types of blood cancers (myeloid leukemias) that have returned or not responded to standard treatments. The main goals are to find a safe dose and see how well people tolerate the drug. About 72 participants …

This study tests a combination of five drugs (fludarabine, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin) in 270 adults with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome that have specific genetic changes. The goal is to see ho…

This study tests whether adding the drug venetoclax to standard chemotherapy can better treat acute myeloid leukemia (AML), a fast-growing blood cancer. About 116 adults with newly diagnosed or returning AML will receive the combination. The goal is to see if the combo improves r…

This early-stage study tests whether drugs that remove extra metals from the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. Researchers want to find the safest dose and see if lowering metal levels in blood…

This study tests a combination of two drugs—CPX-351 (a stronger form of standard chemo) and quizartinib (a targeted therapy)—in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the safest dose and see if the combo can bette…

This study tests a combination of four drugs (cladribine, idarubicin, cytarabine, and quizartinib) in people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that is either newly diagnosed or has returned/not responded to treatment. The goal is to see…

This study tests whether a drug called dexrazoxane can protect the heart from damage caused by chemotherapy in people with certain blood cancers, like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). About 100 participants will receive dexrazoxane alongs…